Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambrosia bidentata pollen, derived from the lanceleaf ragweed plant, is a significant environmental allergen native to North America. This wind-pollinated substance is a primary cause of seasonal allergic rhinitis (hay fever) and asthma in sensitized individuals. While the Ambrosia plant itself has traditional uses in herbal medicine for its anti-inflammatory properties, its pollen is medically recognized for its allergenic potential. In a pharmaceutical context, extracts containing Ambrosia pollen allergens are utilized in allergen immunotherapy to desensitize individuals and reduce the severity of allergic reactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ambrosia bidentata pollen.